Proactive Research Analyst Robin Davison talks to Thomas Warner about his new research note on Tiziana Life Sciences Ltd (NASDAQ:TLSA), which focuses on what he expects from the clinical-stage biopharmaceutical company over the next few months.
He says Tiziana is approaching a significant milestone with the initiation of a planned study for its lead agent, Foralumab in non-active secondary progressive MS.
Meanwhile, data from the existing expanded access protocol study of the same drug is expected to be revealed next month.
Additionally, there's a possibility of scientific data being published at what he describes as the "main MS meeting globally" ECTRIMS scheduled to take place in Milan in October.
He goes on to say that Foralumab is also in development for other indications, including Alzheimer's disease, where they are seeking grant funding from a philanthropic source to potentially conduct a study in 2024.